Trial Profile
A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA BN HER2 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 07 May 2013 Additional lead centre (Bavarian Nordic) added as reported by ClinicalTrials.gov.
- 24 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Jun 2010 Planned number of patients (20), actual start date (Jun 2010) aand official title added as reported by ClinicalTrials.gov.